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Introduction: It is often not possible to determine whether small
nodules detected on computed tomography (CT) in oncology pa-
tients are metastatic. We evaluated a group of oncology patients to
determine the outcome of small pulmonary nodules and whether
they can be ignored in the therapeutic decision process.
Materials and Methods: Radiology reports of thoracic CTs from a
2-year period were searched for keywords indicating a small pul-
monary nodule. All CT images were evaluated by two thoracic
radiologists for nodules 4 mm or less. There were 102 cases that met
criteria for inclusion.
Results: Forty-seven had follow-up CT of less than 365 days, and
55 had follow-up CT for more than 365 days. For those with less
than 365 days, the observed nodule was increased (17, 36%),
increased and new nodules (9, 19%); stable (19, 40%); stable but
new nodules developed (1); and decreased (1). For those with
greater than 365 days follow-up, the observed nodule was increased
(3, 5%); stable (51, 93%); and stable but new nodule developed (1).
Combined, 28% of patient’s nodules increased (90% were within
365 days; 25% within 203 days; and 14% within 14 days).
Conclusion: In oncologic patients, 28% of small pulmonary nodules
detected at initial CT will increase in size, suggesting metastasis.
This increase in size tends to occur early, and follow-up CT in 3
months and 6 months would be appropriate in further evaluation.
Small nodules that are stable in size for more than 365 days are
unlikely to be pulmonary metastasis.
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Advances in computed tomography (CT) imaging have ledto an increased incidental detection of small pulmonary
nodules.1,2 Unfortunately, most of these nodules cannot be
characterized as benign or malignant with CT or other imag-
ing modalities, and it is often not possible to determine the
histologic nature with follow-up imaging.3,4 Additionally,
these nodules are typically too small to biopsy, and definitive
diagnosis is possible only by surgical resection. In the ma-
jority of clinical settings, an interval increase in size of an
isolated pulmonary nodule is considered evidence of metas-
tasis, especially if there is no evidence of metastasis else-
where. Even so, clinical management of patients with small
pulmonary nodules varies and depends on numerous factors
including the risk of malignancy and, to some extent, the
patient and the referring physician.3,5 The Fleischner Society
has published recommendations regarding the management
and further evaluation of small nodules detected on screening
CT. Nevertheless, these recommendations are not applicable
in patients with a preexisting malignancy.6 In fact, in patients
with a preexisting malignancy undergoing evaluation, the
likelihood of malignancy of small pulmonary nodules de-
tected on the initial staging CT is unknown. This lack of data
and knowledge, combined with an absence of an agreed upon
management strategy, can affect the therapeutic management
of oncologic patients. The purpose of our study was to review
our experience in this subset of patients to determine the
long-term outcome of small pulmonary nodules and whether
these nodules can be ignored in the therapeutic decision
process.
MATERIALS AND METHODS
The study was approved by the University of Texas
MD Anderson Cancer Center Institutional Review Board.
Radiology reports of thoracic CT covering a 2-year period
(February 2001 to December 2003) were searched for key-
words that would indicate small pulmonary nodules. The time
frame of 2001 to 2003 was chosen to have a long follow-up
period and also limit studies to those cases using multidetec-
tor CT technology. Follow-up CT imaging was evaluated up
to December 2007. The purpose of the study was to document
interval change or status of the nodule on the last available
CT; therefore only the CT reflecting a nodule change or the
CT at the end of the follow-up at our institution was included
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in our study. Keywords included tiny, very small, subcentimeter,
ditzels, and nodules; using these keywords, 405 patients were
identified. Only patients with CT imaging performed at our
institution were included to minimize the effects of technical
variations in imaging. All CTs were performed using multide-
tector (LightSpeed QX/I, LightSpeed Plus, or LightSpeed VCT;
General Electric Medical Systems, Milwaukee, WI), and base-
line imaging and follow-up imaging were performed using
2.5-mm or 3.75-mm collimation. All patients had histologically
proven malignancy, and none were excluded on the basis of their
primary diagnosis (Table 1).
All CT images were evaluated by two thoracic radiol-
ogists for nodules 4 mm or less in diameter. In cases with
more than one nodule, the largest nodule was used for
determining inclusion in the study group. Patients were elim-
inated from consideration if the nodule(s) was larger than 4
mm, if the nodule was benign (diffusely calcified), if evi-
dence of metastatic disease existed elsewhere, and if there
was no follow-up CT available. Patients with a primary lung
cancer were included if the nodule under question was not in
the same lobe as the primary (i.e., potentially M1a and
nonresectable). Using these criteria, there were 303 cases
excluded from the review: 183 had nodules larger than 4 mm,
102 did not have follow-up imaging, 10 did not have a
confirmed cancer diagnosis, 10 were benign nodules, and one
had metastatic disease elsewhere. This left a study group of
102 cases that met criteria for inclusion. The study group was
divided into those with 365 days of follow-up CT imaging
and those with more than 365 days of follow-up CT imaging.
This division of the study groups by 365 days was used to
parallel the Fleischner Society recommendation of 1-year
follow-up period for small nodules in patients without a
malignancy.
The nodules were measured with electronic calipers
using the institutional picture archiving and communication
systems. Nodules were considered to have had interval
growth by a change in axial size of 1 mm or more, which is
essentially a volumetric doubling in size of a nodule 4 mm or
less. Volumetric analysis tools were not applicable because of
the retrospective nature of this study.
RESULTS
Of the 102 cases, 47 had follow-up CT of 365 days,
and 55 had follow-up of more than 365 days.
Follow-Up CT of Less Than 365 Days (n  47
Patients)
Of the 47 patients with follow-up CT of 365 days,
there were 22 women and 25 men with an average age of 57
years (range, 9–82). The primary malignancies were bladder
(one), breast (three), colorectal (eight), esophageal (one),
giant cell tumor (one), lung (five), melanoma (six), mesothe-
lioma (one), malignant fibrous histiocytoma (two), oropha-
ryngeal (three), osteosarcoma (three), ovarian (one), pancre-
atic (one), peritoneal (one), prostate (one), renal cell (four),
scalp adenocarcinoma (one), testicular (one), thyroid (two),
and unknown primary (one). Treatment of the primary dis-
ease consisted of chemotherapy only (four), chemotherapy/
radiation therapy (RT) (two), radiofrequency ablation (one),
surgery only (nine), surgery/chemotherapy (21), surgery/che-
motherapy/RT (six), surgery/RT (three), and RT only (one).
The number of nodules identified was multiple in 39
patients and solitary in eight patients. Of the patients with
multiple nodules, five had two nodules, seven had three
nodules, and 27 had more than three nodules. Of the cases
with multiple nodules, 21 had an increase in size, 17 cases
were stable, and one decreased in size.
The interval between baseline CT and follow-up was an
average of 210 days (range, 63–257). The status of the
observed nodules was increased in size (17, 36% [95%
confidence interval, CI: 22–50%]), increased in size and new
nodules (nine, 19% [95% CI: 8–30%]); stable (19, 40% [95%
CI: 26–54%]); stable but new nodules developed (one); and
decreased in size (one). There were 26 (55% [95% CI:
41–69%]) patients with an increase in nodule size, and the
average time to increase in size was 203 days (range, 63–355
days). The average time to increase was 174 days (range,
75–301) in the 17 nodules that increased in size and 256 days
(range, 63–355) in the nine patients with nodules that in-
creased in size and number. The observed change in size of
the nodules was an average of 5 mm (range, 1–13) of which
only two were 1 mm.
TABLE 1. Primary Malignancy and Nodule Status
Primary Diagnosis
Nodule Status
Increased Stable Decreased
Melanoma 4 13
Lung 3 9
Colon/colorectal 6 4
Breast 1 8 1
Sarcoma 8
Renal cell carcinoma 4 4
Oropharyngeal 4
Leiomyosarcoma 1 3
Osteosarcoma 3
Thyroid 1 2
Liposarcoma 3
Malignant fibrous histiocytoma 1 1
Pancreatic 1 1
Bladder 1 1
Esophageal 1
Giant cell tumor 1
Hemangiopericytoma 1
Meso 1
Ovarian 1
Parotid 1
Penile 1
Peritoneal 1
Prostate 1
Scalp 1
Skin 1
Testicular 1
Thymoma 1
Unknown primary 1
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Of the 26 patients with an increase in nodule size, 20
(77%) had undergone chemotherapy; 12 (71%) of the 17
patients with an increase in size only and eight (89%) of the
nine patients with an increase in size and number. Of the 19
stable nodules, 11 (58%) patients had undergone chemother-
apy, and the one patient with a nodule that decreased in size
had also undergone chemotherapy.
Follow-Up CT of More Than 365 Days (n  55
Patients)
Of the 55 patients with follow-up CT of more than
365 days, there were 30 women and 25 men with an
average age of 57 years (range, 14 – 81). The primary
malignancies were bladder (one), breast (seven), colorectal
(two), hemangiopericytoma (one), leiomyosarcoma (four),
liposarcoma (three), lung (seven), melanoma (11), oropha-
ryngeal (one), pancreatic (one), parotid (one), penile (one),
renal cell (four), sarcoma (eight), skin squamous cell carci-
noma (one), thymoma (one), and thyroid (one). Treatment of
the primary disease consisted of chemotherapy only (one),
chemotherapy/RT (five), surgery only (20), surgery/chemo-
therapy (13), surgery/chemotherapy/RT (nine), surgery/RT
(six), and RT only (one).
The number of nodules identified was multiple in 43
patients and solitary in 12 patients. Of the patients with
multiple nodules, 13 had two nodules, seven had three nod-
ules, and 23 had more than three nodules. None of the
multiple nodule cases demonstrated an increase in size; an
increase only occurred in cases with solitary nodules. The
interval between baseline CT and follow-up was an average
of 1259 days (range, 365–2113). The status of the observed
nodules was increased in size (three, 5% [95% CI: 0–11%]),
stable (51, 93% [95% CI: 89–100%]), and stable but new
nodule developed (one). Regarding the three nodules that
increased in size, this increase occurred at 413 days (primary
colon malignancy treated with surgery and chemotherapy),
438 days (primary renal cell carcinoma treated with surgery
only), and 730 days (primary leiomyosarcoma of the uterus
treated with surgery and chemotherapy) (mean 527, range,
413–730 days). The observed increase in size was 5 mm, 7
mm, and 7 mm, respectively. For those patients with stable
nodule size, the average interval was 1069 days (range,
365–2113). Of the 51 stable nodules, one (2%) patient had
undergone chemotherapy; five (10%) chemotherapy/RT, 19
(37%) surgery only, 11 (22%) surgery/chemotherapy, nine
(18%) surgery/chemotherapy/RT, and six (12%) surgery/RT.
Of the stable nodule group, a total of 26 (51%) had chemo-
therapy as part of their treatment.
Combined Cases
When all cases were combined, there were 29 (28%
[95% CI: 19–37%]) patients whose nodule increased in size.
In most of the nodules (90%), the increase occurred on
follow-up CT within 365 days (range, 63–355). In 25%
(26/102), interval growth occurred within 203 days and in
14% (14/102) an increase occurred in less than 14 days.
Overall, nodules with follow-up of less than 365 days were
more likely to increase in size than those with follow-up of
more than 365 days (p  0.001).
DISCUSSION
The incidental detection of indeterminate small nodules
on chest CT performed in oncology patients for staging or
follow-up is not uncommon and generates much anxiety for
oncologists and radiologists. The conventional historical
standard for noninvasive management of pulmonary nodules
of uncertain etiology has been, until recently, follow-up
imaging to establish stability for 2 years before considering
the nodule to be benign.7,8 Recently, it has been questioned
whether the use of a 2-year stability is accurate in determin-
ing benignity because this recommendation was not appro-
priately validated, was implemented before the advent of CT,
and pertains to nodules larger than 1 cm in diameter.6,9 Also
concerning is that studies of nodules less than 1 cm detected
on thoracic CT and resected by video-assisted thoracoscopic
surgery were proved to have a relatively high likelihood of
malignancy (48–58%) and even higher in those patients with
a preexisting malignancy (62–81%).10,11 In an effort to ad-
dress some concerns of small nodule detected at CT, the
Fleischner Society published guidelines for the management
of small nodules. Their findings were based on an evaluation
of data from lung cancer screening trials and indicated that
less than 1% of small (less than 5 mm) pulmonary nodules are
malignant.6,12,13 Nevertheless, the implications of small nod-
ules in oncology patients is much different than other pa-
tients, and it is not always practical to wait for long-term
follow-up results. Unfortunately, the likelihood of malig-
nancy of small pulmonary nodules of 4 mm or less detected
on CT in patients with a preexisting diagnosis of a primary
malignancy has not been reported.
The results of our study show that 28% of patients with
small (4 mm or less) nodules on the initial staging CT, based
on interval growth, will have malignant nodules. This is a
significant difference compared with data from lung cancer
screening trials. Specifically, Midthun14 reported that the
likelihood of malignancy for nodules smaller than 3 mm was
0.2% and 0.9% for nodules 4 to 7 mm in diameter. This low
incidence of malignancy is reflected in the Fleischner Society
guidelines that recommend that no follow-up is required for
nodules detected incidentally at nonscreening CT in low-risk
patients and at 12 months in high-risk patients with no
additional assessment recommended if the nodule is stable in
size. The findings of our study confirm that the Fleischner
Society guidelines for the management of small pulmonary
nodules detected on screening CT do not apply to oncologic
patients. It is important to note that the Fleischner Society
guidelines have a caveat to indicate that its recommendations
do not apply to patients known to have or suspected of having
malignant disease. Although the guidelines recommend that
patients with a malignancy should be cared for “according to
the specific clinical situation” with pertinent factors to be
considered, such as stage of malignancy, and whether early
detection of metastases will affect care, no specific follow-up
regarding frequency of CT imaging is indicated.
In our study, of the 29 patients with an increase in size
of nodules, the increase occurred in most patients within 365
days. This increase occurred in 15% within 3 months and in
approximately 25% at 6 months. Accordingly, the interval for
Munden et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1960
further CT evaluation of a small nodule in an oncologic
patient that could potentially affect clinical management
should be for 3 months for the first year after detection
(Figure 1). There were only three nodules that increased in
size after more than 1 year. Therefore, if a 1-year follow-up
CT shows stability of small nodules, it is likely that these
nodules are not malignant, and additional follow-up at
6-month intervals for a year would be appropriate to exclude
malignancy in most oncologic patients. Subsequent follow-up
imaging should be according to the relevant protocol or
specific clinical scenario. Although a possible selection bias,
it does not seem that selection bias for tumors that are less
likely to metastasize to the lungs has occurred in the more
than 365-day follow-up group because 33 (60%) of the 55
patients with more than 365-day follow-up had primary
tumors that commonly metastasize to the lungs: seven breast,
seven lung, 11 melanoma, and eight sarcoma patients. It is
also possible that the use of chemotherapy could potentially
affect the natural temporal evolution and growth of malignant
lung nodules. Nevertheless, in the less than 1-year follow-up
group of those patients with an increase in nodule size, 77%
were undergoing chemotherapy. This would suggest that
undergoing chemotherapy does not negate the importance of
follow-up CT evaluation of nodules 4 mm or less in diameter.
There are limitations of this study inherent in all retro-
spective analyses of data such as the variability of the time
intervals between baseline and follow-up CT. Nevertheless,
appropriate clinical follow-up is determined by the standard
of care for a specific primary malignancy; therefore, it is not
possible or appropriate to have standardized follow-up CT at
predetermined time intervals. Additionally, the divergent na-
ture of the primary malignancies could also contribute to the
likelihood of nodule growth. Retrospective database searches
also lend themselves to missing potential cases that would
have met the inclusion criteria. The study would also be
strengthened by a larger sample size, but the difficulty in
acquiring the appropriate data in oncologic patients limits the
likelihood of large sample size collection. Additionally, fol-
low-up imaging was performed at a thinner collimation in
some patients (a reflection of changing the routine slice
collimation from 3.75 to 2.5 mm in our institution) and
potentially could have affected the accuracy of the determi-
nation of a change in size of nodules. Another limitation is
the determination of malignancy based on an increase in size
of a nodule is empirical. Without pathologic confirmation, the
malignant potential of these nodules could be over or under-
estimated. Unfortunately, obtaining pathologic confirmation
is unlikely in these patients, and our methods reflect common
clinical practice. Finally, inherent limitations in measuring
lesions cannot be avoided with current technology. This is
compounded by usage of electronic calipers for small nod-
ules. Even though less than ideal, electronic calipers were felt
to be more reliable than visual analysis or manual ruler
technique and, therefore, were used to the best of our abili-
ties. To fully understand the significance of small pulmonary
nodules in oncologic patients, a prospective study with strat-
ification of patients based on type of malignancy and patho-
logic confirmation would have to be performed.
In summary, in 28% of oncologic patients, small pul-
monary nodules detected at initial CT will increase in size,
suggesting metastatic disease. This increase tends to occur
early, and initial follow-up CT in 3 months and subsequently
at 3-month intervals for a year would be appropriate in
further evaluation. Small nodules that are stable in size for
more than 365 days are unlikely to be pulmonary metas-
tases, but additional follow-up at 6-month intervals for
another year would be appropriate to exclude metastases in
most oncologic patients.
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